Search results for "Injection"

showing 10 items of 920 documents

UDP-glucose deficiency in a mutant cell line protects against glucosyltransferase toxins from Clostridium difficile and Clostridium sordellii.

1996

Abstract We have previously isolated a fibroblast mutant cell with high resistance to the two Rho-modifying glucosyltransferase toxins A and B of Clostridium difficile. We demonstrate here a low level of UDP-glucose in the mutant, which explains its toxin resistance since: (i) to obtain a detectable toxin B-mediated Rho modification in lysates of mutant cells, addition of UDP-glucose was required, and it promoted the Rho modification dose-dependently; (ii) high pressure liquid chromatography analysis of nucleotide extracts of cells indicated that the level of UDP-glucose in the mutant (0.8 nmol/106 cells) was lower than in the wild type (3.7 nmol/106 cells); and (iii) sensitivity to toxin B…

Uridine Diphosphate GlucoseMicroinjectionsMutantBacterial ToxinsClostridium difficile toxin AClostridium sordelliiClostridium difficile toxin Bmedicine.disease_causeBiochemistryMicrobiologyCell LineCricetulusBacterial ProteinsGTP-Binding ProteinsCricetinaemedicineAnimalsMolecular BiologyClostridiumbiologyToxinClostridioides difficileWild typeCell BiologyClostridium difficilebiology.organism_classificationGlucosyltransferasesMutationbiology.proteinGlucosyltransferaseThe Journal of biological chemistry
researchProduct

The study of myocardial viability after myocardial infarction: Valve and limitations of magnetic resonance imaging compared with myocardial scintigra…

1997

International audience; Abstract: The aim of this study was to compare myocardial thickness measured by magnetic resonance imaging and quantified fixation of thallium. Twenty-one patients 61.2+/-11 years were investigated after myocardial infarction of the anterior wall in 8 cases, inferior in 10 cases, lateral in 2 cases and apical in one case. The mean angiographic ejection fraction was 46.5 +/- 19 %. Myocardial scintigraphy was performed after an exercise or pharmacological stress test and followed by a study of redistribution. The data was analysed by a quantitative method. Magnetic resonance imaging was performed with Vertical and horizontal long axis views in systole and diastole with…

VIABLE MYOCARDIUMF-18 FLUORODEOXYGLUCOSELEFT-VENTRICULAR DYSFUNCTION[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingCORONARY-ARTERY DISEASEPOSITRON EMISSION TOMOGRAPHYTL-201[INFO.INFO-IM]Computer Science [cs]/Medical Imaging[INFO.INFO-IM] Computer Science [cs]/Medical ImagingTHALLIUM UPTAKEREVASCULARIZATIONREINJECTIONIRREVERSIBLE DEFECTS
researchProduct

Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting

2021

Objectives To investigate the real-life experience of patients affected by neovascular age-related macular degeneration (nAMD), in the healthcare pathway for the management of the disease, using a "patient journey" and narrative method approach. Methods The patient journey of subjects affected by nAMD was designed using a process-mapping methodology involving a team from 11 Italian centres. Subsequently, narratives were collected from nAMD patients and family members. The interviews were analyzed using the narrative medicine methodology. Results Eleven specialized retina centres across Italy were involved and 205 narratives collected. In 29% of cases, patients underestimated their symptoms …

Vascular Endothelial Growth Factor Amedicine.medical_specialtyActivities of daily livingage related macular degenerationMEDLINEAngiogenesis InhibitorsDiseaseArticle03 medical and health sciencesMacular Degeneration0302 clinical medicineMultidisciplinary approachRanibizumabHealth carereal lifeMedicinepatient journeyHumansNarrativeeducationNarrative medicineeducation.field_of_studyNarrative medicine wet AMDbusiness.industrySettore MED/30 - Malattie Apparato VisivoNarrative MedicineMacular degenerationmedicine.diseaseOphthalmologyFamily medicineIntravitreal Injections030221 ophthalmology & optometryQuality of LifeWet Macular Degenerationbusiness030217 neurology & neurosurgery
researchProduct

Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy.

2010

Aims Currently, it is still unclear which mechanisms drive metabolic benefits after angiogenic gene therapy. The side-effect profile of efficient angiogenic gene therapy is also currently incompletely understood. In this study, the effects of increasing doses of adenoviral (Ad) vascular endothelial growth factor-A (VEGF-A) were evaluated on vascular growth, metabolic benefits, and systemic side effects. Methods and results Adenoviral vascular endothelial growth factor-A or AdLacZ control was injected intramuscularly (109–1011 vp/mL) or intra-arterially (5 × 1011 vp/mL) into rabbit ( n = 102) hindlimb muscles and examined 6 or 14 days later. Blood flow, tissue oedema, metabolic benefits, and…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisGenetic VectorsNeovascularization PhysiologicEnzyme-Linked Immunosorbent Assayta3111Injections IntramuscularAdenoviridaeNeovascularizationchemistry.chemical_compoundInternal medicinemedicineAnimalsMuscle SkeletalUltrasonography InterventionalSprouting angiogenesisDose-Response Relationship Drugbusiness.industryGene Transfer TechniquesMetabolic acidosisGenetic Therapymedicine.diseaseCapillariesHindlimbVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistryLac OperonCirculatory systemRabbitsmedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionEuropean heart journal
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct

POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPI…

2017

Purpose: To assess the effect of topical antibiotic prophylaxis on postoperative endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.Methods: A systematic literature search was performed from inception to March 2016 using PubMed, Medline, Web of Science, Embase, and the Cochrane Library, to identify articles that reported cases of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. We used a pooled analysis to estimate the incidence of cases of endophthalmitis who developed after injections performed with and without topical antibiotic prophylaxis. We used regression analysis to explore the effects of stu…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyEye InfectionsVisual AcuityAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection;Angiogenesis InhibitorsCochrane LibraryGlobal HealthEye Infections Bacteriallaw.invention03 medical and health sciencestopical antibiotic prophylaxis; postoperative endophthalmitis; anti–vascular endothelial growth factor agents; intravitreal injectionpostoperative endophthalmitis0302 clinical medicineEndophthalmitisRandomized controlled triallawtopical antibiotic prophylaxisanti–vascular endothelial growth factor agentsInternal medicinemedicineantibiotic prophylaxiHumansanti-vascular endothelial growth factor030212 general & internal medicineAntibiotic prophylaxisProspective cohort studyAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuityEndophthalmitisbusiness.industryIncidence (epidemiology)Bacterialintravitreal injectionRetrospective cohort studyGeneral MedicineEye infectionAntibiotic Prophylaxismedicine.diseaseAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections; Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuitySurgeryAnti-Bacterial AgentsOphthalmologyendophthalmitiIntravitreal Injections030221 ophthalmology & optometryAnti–vascular endothelial growth factorbusiness
researchProduct

Priming with a combination of proangiogenic growth factors improves wound healing in normoglycemic mice

2011

Growth factors and/or angiogenic factors are supposed to improve wound healing. The aim of our study was to evaluate the effects of subcutaneous pretreatment with combinatory proangiogenic factors on wound closure, mechan - ical properties, vessel density and morphology. Twenty-eight Balb/c mice were divided equally into two groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg) and P dGF (3.5 µg) was administered subcutaneously 3, 5 and 7 days to 14 mice before full thickness skin punch biopsy wounding, whereas 14 control animals received three injections of 0.2 ml saline solution. Wound sizes were assessed daily and the repaired tissues were harvested 7 days after complete wound closure. Comp…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyPlatelet-derived growth factormedicine.medical_treatmentInjections SubcutaneousUrologyPriming (immunology)Neovascularization PhysiologicArticlechemistry.chemical_compoundMiceSkin Physiological PhenomenaTensile StrengthGeneticsmedicineAnimalsRegenerationSalineSkinPlatelet-Derived Growth FactorMice Inbred BALB CWound HealingOncogeneintegumentary systembusiness.industryGeneral MedicineMolecular medicineSurgeryVascular endothelial growth factor ADrug CombinationsCollagen Type IIIchemistryApoptosisThermographyBlood VesselsAngiogenesis Inducing AgentsFemaleFibroblast Growth Factor 2Wound healingbusiness
researchProduct

Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis

2020

Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Res…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyretinaretinal pathology/researchVisual AcuityAngiogenesis InhibitorsTreat and extendlaw.inventionMacular DegenerationRandomized controlled trialClinical Protocolsretina – medical therapieslawInternal medicineAge relatedRanibizumabMedicineHumansbusiness.industryAge-related macular degenerationGeneral MedicineMacular degenerationpediatric ophthalmologyretina – medical therapiemedicine.diseaseOphthalmologyRegimenTreatment OutcomeMeta-analysisvitreous/retinal diseaseIntravitreal InjectionsWet Macular DegenerationPediatric ophthalmologypharmacologybusinessTomography Optical CoherenceAge-related macular degeneration; pediatric ophthalmology; pharmacology; retina; retina – medical therapies; retinal pathology/research; vitreous/retinal disease
researchProduct

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

2022

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 m…

Vascular Endothelial Growth Factor Atype 3 neovascularization.brolucizumabNeovascularization PathologicVisual Acuityneovascular age-related macular degeneration; type 3 neovascularization; retinal angiomatous proliferation; brolucizumab; optical coherence tomography angiography; intravitreal injectionintravitreal injectionretinal angiomatous proliferationEndothelial Growth Factorsneovascular age-related macular degenerationGeneral MedicineAntibodies Monoclonal Humanizedoptical coherence tomography angiographyIntravitreal InjectionsHumansFluorescein AngiographyTomography Optical CoherenceRetrospective StudiesMedicina
researchProduct

Run-Time Reconfiguration for Emulating Transient Faults in VLSI Systems

2006

Advances in circuitry integration increase the probability of occurrence of transient faults in VLSI systems. A confident use of these systems requires the study of their behaviour in the presence of such faults. This study can be conducted using model-based fault injection techniques. In that context, field-programmable gate arrays (FPGAs) offer a great promise by enabling those techniques to execute models faster. This paper focuses on how run-time reconfiguration techniques can be used for emulating the occurrence of transient faults in VLSI models. Although the use of FPGAs for that purpose has been restricted so far to the well-known bit-flip fault model, recent studies in fault repres…

Very-large-scale integrationEmulationComputer sciencebusiness.industryEmbedded systemControl reconfigurationContext (language use)Transient (computer programming)Hardware_PERFORMANCEANDRELIABILITYFault injectionFault modelFault (power engineering)businessInternational Conference on Dependable Systems and Networks (DSN'06)
researchProduct